Raymond James & Associates’s Mirum Pharmaceuticals MIRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $5.37M | Sell |
137,628
-6,586
| -5% | -$257K | ﹤0.01% | 1612 |
|
|
2024
Q2 | $4.93M | Buy |
144,214
+13,651
| +10% | +$467K | ﹤0.01% | 1585 |
|
|
2024
Q1 | $3.28M | Sell |
130,563
-5,119
| -4% | -$129K | ﹤0.01% | 1857 |
|
|
2023
Q4 | $4.01M | Buy |
135,682
+29,475
| +28% | +$870K | ﹤0.01% | 1676 |
|
|
2023
Q3 | $3.36M | Buy |
106,207
+38,619
| +57% | +$1.22M | ﹤0.01% | 1706 |
|
|
2023
Q2 | $1.75M | Buy |
67,588
+39,001
| +136% | +$1.01M | ﹤0.01% | 2132 |
|
|
2023
Q1 | $687K | Buy |
28,587
+8,834
| +45% | +$212K | ﹤0.01% | 2700 |
|
|
2022
Q4 | $385K | Sell |
19,753
-51,256
| -72% | -$999K | ﹤0.01% | 3051 |
|
|
2022
Q3 | $1.49M | Buy |
71,009
+25,439
| +56% | +$535K | ﹤0.01% | 2146 |
|
|
2022
Q2 | $887K | Buy |
45,570
+33,472
| +277% | +$652K | ﹤0.01% | 2522 |
|
|
2022
Q1 | $266K | Sell |
12,098
-6,555
| -35% | -$144K | ﹤0.01% | 3460 |
|
|
2021
Q4 | $298K | Sell |
18,653
-1,212
| -6% | -$19.4K | ﹤0.01% | 3426 |
|
|
2021
Q3 | $396K | Buy |
19,865
+5,991
| +43% | +$119K | ﹤0.01% | 3213 |
|
|
2021
Q2 | $240K | Sell |
13,874
-20,000
| -59% | -$346K | ﹤0.01% | 3552 |
|
|
2021
Q1 | $671K | Buy |
33,874
+541
| +2% | +$10.7K | ﹤0.01% | 2784 |
|
|
2020
Q4 | $582K | Buy |
+33,333
| New | +$582K | ﹤0.01% | 2695 |
|
|
2020
Q1 | – | Sell |
-8,843
| Closed | -$217K | – | 3512 |
|
|
2019
Q4 | $217K | Buy |
+8,843
| New | +$217K | ﹤0.01% | 3270 |
|